Leidos, a national security, health, and engineering solutions company, has donated $40,000 to the Georgia Institute of Technology to fund a pilot program in healthcare data analytics. The funding will help support the development of a pilot data analytics platform in the I3L designed to improve the quality and efficiency of healthcare through data transparency. The donation marks Leidos’ third to Tech’s Interoperability & Integration Innovation Lab (I3L) since 2013.
Healthcare Data Analytics Pilot Details
I3L, a program of Tech’s Enterprise Innovation Institute, is a virtual and physical laboratory for health information technology. The pilot project underscores a statewide effort to ensure a healthier Georgia workforce. Leidos’ donation will continue to support health informatics students working on the collaborative pilot.
In turn, that will support I3L’s efforts in the Triple Aim Initiative and its core three areas:
1. making the patient care experience better
2. improving population health
3. reducing the per capita cost of healthcare.
I3L is collaborating with the Georgia Department of Public Health, the University of Georgia Public Health Department, and a consortium of employers.
“We are so appreciative of this third-year gift and Leidos’ commitment to technology in the healthcare and information technology spaces,” said Steve Rushing, I3L’s senior strategic advisor in a statement. “This donation allows us to build out a robust aggregate dataset and better define the information employers want in order to optimize the value of their healthcare expenditures.”
Leidos was recently awarded the DoD EHR Modernization contract alongside Cerner and Accenture Federal Service valued at over $4.33 billion will serve 55 hospitals and 600 clinics and must be interoperable with other EHRs. The company was also recently awarded a prime contract by the U.S. Army to provide medical product and research development to the U.S. Army Medical Research and Materiel Command (USAMRMC). The multiple-award indefinite-delivery/indefinite-quantity contract has a five-year base period of performance, five-one year options worth a total value of $900 million for all awardees, if all options are exercised.
